Company Overview of Knoll SpA
Knoll SpA detects pharmacological agents in the treatment of the main human diseases. The company started with products for treating cardiovascular disease, mainly through the synthesis of Verapamil. Thereafter the company started working on some other cardiac diseases, such as arrhythmia, hypertension and cardiac decompensation. The company focuses on areas such as obesity, depression, metabolic deficiencies, tissue repair, and throat. The company was founded in 1929 and is headquartered in Muggio', Italy.
Viale Europa, 35
Founded in 1929
39 39 24426
39 39 795014
Key Executives for Knoll SpA
Similar Private Companies By Industry
|A. Menarini Industrie Farmaceutiche Riunite Srl||Europe|
|Aboca S.p.A. - Societa Agricola||Europe|
|ACS Dobfar S.p.A.||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Knoll SpA, please visit www.knoll-farma.it. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.